TECHNE CORPORATION

FORM 10-Q

SEPTEMBER 30, 2007

INDEX

PAGE NO.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (unaudited)

Condensed Consolidated Balance Sheets as of September 30, 2007 and June 30, 2007 3

Condensed Consolidated Statements of Earnings for the Quarter Ended September 30, 2007 and 2006 4

Condensed Consolidated Statements of Cash Flows for the Quarter Ended September 30, 2007 and 2006 5
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 4. CONTROLS AND PROCEDURES

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 1A. RISK FACTORS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SHAREHOLDERS

ITEM 5. OTHER INFORMATION

ITEM 6. EXHIBITS

SIGNATURES

PART I. FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

TECHNE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
(unaudited)

<table>
<thead>
<tr>
<th>9/30/07</th>
<th>6/30/07</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASSETS</td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>$144,745</td>
</tr>
<tr>
<td>Short-term available-for-sale investments</td>
<td>36,249</td>
</tr>
<tr>
<td>Trade accounts receivable, net</td>
<td>30,673</td>
</tr>
<tr>
<td>Other receivables</td>
<td>1,362</td>
</tr>
<tr>
<td>Inventories</td>
<td>9,281</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>7,746</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>1,153</td>
</tr>
<tr>
<td>Total current assets</td>
<td>231,209</td>
</tr>
<tr>
<td>Available-for-sale investments</td>
<td>97,851</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>93,385</td>
</tr>
<tr>
<td>Goodwill, net</td>
<td>25,068</td>
</tr>
<tr>
<td>Intangible assets, net</td>
<td>4,811</td>
</tr>
<tr>
<td>Deferred income taxes</td>
<td>4,257</td>
</tr>
<tr>
<td>Investments in unconsolidated entities</td>
<td>23,909</td>
</tr>
<tr>
<td>Other assets</td>
<td>566</td>
</tr>
<tr>
<td>$481,056</td>
<td>$454,844</td>
</tr>
</tbody>
</table>

LIABILITIES AND STOCKHOLDERS’ EQUITY

<table>
<thead>
<tr>
<th>9/30/07</th>
<th>6/30/07</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trade accounts payable</td>
<td>$ 5,447</td>
</tr>
<tr>
<td>Salaries, wages and related accruals</td>
<td>3,397</td>
</tr>
<tr>
<td>Other accounts payable and accrued expenses</td>
<td>1,932</td>
</tr>
<tr>
<td>Income taxes payable</td>
<td>4,024</td>
</tr>
<tr>
<td>Total current liabilities</td>
<td>14,800</td>
</tr>
</tbody>
</table>
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,524,378 and 39,455,677, respectively 395 395
Additional paid-in capital 112,904 109,993
Retained earnings 337,411 314,339
Accumulated other comprehensive income 15,546 12,924

Total stockholders' equity 466,256 437,651

$481,056 $454,844

See notes to condensed consolidated financial statements.

### TECHNE CORPORATION AND SUBSIDIARIES
### CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(in thousands, except per share data)
(unaudited)

<table>
<thead>
<tr>
<th></th>
<th>9/30/07</th>
<th>9/30/06</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>$ 57,987</td>
<td>$ 52,351</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>12,104</td>
<td>11,237</td>
</tr>
<tr>
<td><strong>Gross margin</strong></td>
<td>45,883</td>
<td>41,114</td>
</tr>
<tr>
<td><strong>Operating expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selling, general and administrative</td>
<td>8,090</td>
<td>7,067</td>
</tr>
<tr>
<td>Research and development</td>
<td>5,181</td>
<td>4,855</td>
</tr>
<tr>
<td>Amortization of intangible assets</td>
<td>288</td>
<td>403</td>
</tr>
<tr>
<td><strong>Total operating expenses</strong></td>
<td>13,559</td>
<td>12,325</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>32,324</td>
<td>28,789</td>
</tr>
<tr>
<td><strong>Other expense (income):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest expense</td>
<td>--</td>
<td>268</td>
</tr>
<tr>
<td>Interest income</td>
<td>(2,998)</td>
<td>(1,676)</td>
</tr>
<tr>
<td>Other non-operating expense, net</td>
<td>569</td>
<td>485</td>
</tr>
<tr>
<td><strong>Total other income</strong></td>
<td>(2,429)</td>
<td>(923)</td>
</tr>
<tr>
<td><strong>Earnings before income taxes</strong></td>
<td>34,753</td>
<td>29,712</td>
</tr>
<tr>
<td><strong>Income taxes</strong></td>
<td>11,681</td>
<td>10,081</td>
</tr>
<tr>
<td><strong>Net earnings</strong></td>
<td>$ 23,072</td>
<td>$ 19,631</td>
</tr>
</tbody>
</table>

Earnings per share:
- Basic $0.58 $0.50
- Diluted $0.58 $0.50

Weighted average common shares outstanding:
- Basic 39,489 39,379
- Diluted 39,587 39,469

See notes to condensed consolidated financial statements.
THREE MONTHS ENDED  
--------------------  
9/30/07  9/30/06
--------  --------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings                                           $ 23,072   $ 19,631
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization                          1,692      1,665
Deferred income taxes                                   (192)      (95)
Stock-based compensation expense                       170        165
Excess tax benefit from stock option exercises          (328)       (24)
Losses by equity method investees                       257        127
Other                                                   19         2
Change in operating assets and operating liabilities, net of acquisitions:
Trade accounts and other receivables                  (670)      (443)
Inventories                                            (490)      (132)
Prepaid expenses                                       (250)       (94)
Trade, other accounts payable and accrued expenses    397        127
Salaries, wages and related accruals                 (1,139)    (1,019)
Income taxes payable                                  (99)       (484)
--------  --------
Net cash provided by operating activities          22,637     19,387
--------  --------
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment                  (3,230)    (1,899)
Purchase of available-for-sale investments           (19,190)    (4,275)
Proceeds from sales of available-for-sale investments 1,235      1,234
Proceeds from maturities of available-for-sale investments 4,900      1,320
Increase in other assets                              (243)       --
Increase in investments in unconsolidated entities     --      (7,200)
--------  --------
Net cash used in investing activities            (16,528)   (10,820)
--------  --------
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock                               2,319        146
Excess tax benefit from stock option exercises          328        24
Purchase of common stock for stock bonus plans        (1,494)     (1,222)
Payments on long-term debt                              --       (292)
--------  --------
Net cash provided (used) by financing activities    1,153     (1,344)
--------  --------
Effect of exchange rate changes on cash            1,998       970
--------  --------
Net increase in cash and cash equivalents             9,260      8,193
Cash and cash equivalents at beginning of period  135,485    89,634
--------  --------
Cash and cash equivalents at end of period         $144,745   $ 97,827
--------  --------
See notes to condensed consolidated financial statements.

5

TECHNE CORPORATION & SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

A. BASIS OF PRESENTATION:
The unaudited condensed consolidated financial statements of Techne Corporation and subsidiaries (the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.

A summary of significant accounting policies followed by the Company is
detailed in the Company's Annual Report on Form 10-K for fiscal 2007. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2007 included in the Company's Annual Report to Shareholders for fiscal 2007.

Recent Accounting Pronouncements:

In June 2006, the FASB issued Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109. Effective July 1, 2007, the Company adopted FIN 48. FIN 48 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Adoption of FIN 48 did not materially impact the consolidated financial statements for the quarter ended September 30, 2007.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. The Statement establishes a single authoritative definition of fair value, sets out a framework for measuring fair value, and requires additional disclosures about fair value measurements. SFAS No. 157 applies only to fair value measurements that are already required or permitted by other accounting standards and is effective for the Company in fiscal 2009. The Company is currently evaluating the impact of adopting SFAS No. 157.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities. The Statement permits entities to choose to measure certain financial instruments at fair value. Unrealized gains and losses on items for which the fair value option has been elected are reported in earnings at each subsequent reporting date. SFAS No. 159 is effective for the Company in fiscal 2009. The Company is currently evaluating the impact of adopting SFAS No. 159.

Certain consolidated balance sheet captions appearing in this interim report are as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>9/30/07</th>
<th>6/30/07</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRADE ACCOUNTS RECEIVABLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trade accounts receivable</td>
<td>$30,817</td>
<td>$29,700</td>
</tr>
<tr>
<td>Less allowance for doubtful accounts</td>
<td>144</td>
<td>141</td>
</tr>
<tr>
<td>NET TRADE ACCOUNTS RECEIVABLE</td>
<td>$30,673</td>
<td>$29,559</td>
</tr>
<tr>
<td>INVENTORIES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raw materials</td>
<td>$3,712</td>
<td>$3,821</td>
</tr>
<tr>
<td>Supplies</td>
<td>108</td>
<td>125</td>
</tr>
<tr>
<td>Finished goods</td>
<td>5,461</td>
<td>4,811</td>
</tr>
<tr>
<td>TOTAL INVENTORIES</td>
<td>$9,281</td>
<td>$8,757</td>
</tr>
<tr>
<td>PROPERTY AND EQUIPMENT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Land</td>
<td>$4,214</td>
<td>$4,214</td>
</tr>
<tr>
<td>Buildings and improvements</td>
<td>100,946</td>
<td>100,617</td>
</tr>
<tr>
<td>Building construction in progress</td>
<td>5,660</td>
<td>3,205</td>
</tr>
<tr>
<td>Laboratory equipment</td>
<td>20,950</td>
<td>20,657</td>
</tr>
<tr>
<td>Office equipment</td>
<td>4,580</td>
<td>4,407</td>
</tr>
<tr>
<td>Leasehold improvements</td>
<td>978</td>
<td>975</td>
</tr>
<tr>
<td>LESS ACCUMULATED DEPRECIATION AND AMORTIZATION</td>
<td>137,328</td>
<td>134,075</td>
</tr>
<tr>
<td>NET PROPERTY AND EQUIPMENT</td>
<td>$93,385</td>
<td>$91,535</td>
</tr>
<tr>
<td>INTANGIBLE ASSETS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Customer relationships $ 20,200 $ 20,200
Technology 4,213 4,213
Trade names and trademarks 1,396 1,396
Supplier relationships 14 14

------- -------
25,823 25,823

Less accumulated amortization 21,012 20,724

------- -------
NET INTANGIBLE ASSETS $  4,811 $  5,099

-------- -------
ACCUMULATED OTHER COMPREHENSIVE INCOME:
Foreign currency translation adjustments $ 15,617 $ 13,400
Unrealized losses on available-for-sale investments (71) (476)

------- -------
TOTAL ACCUMULATED OTHER COMPREHENSIVE INCOME $ 15,546 $ 12,924

-------- -------

B. EARNINGS PER SHARE:

Shares used in the earnings per share computations are as follows (in thousands):

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>9/30/07</th>
<th>9/30/06</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weighted average common shares outstanding-basic</td>
<td>39,489</td>
<td>39,379</td>
</tr>
<tr>
<td>Dilutive effect of stock options and warrants</td>
<td>98</td>
<td>90</td>
</tr>
<tr>
<td>Weighted average common shares outstanding-diluted</td>
<td>39,587</td>
<td>39,469</td>
</tr>
</tbody>
</table>

The dilutive effect of stock options and warrants in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 46,000 and 37,000 for the quarters ended September 30, 2007, and 2006, respectively.

C. SEGMENT INFORMATION:

The Company has three reportable operating segments based on the nature of products and geographic location: biotechnology, R&D Systems Europe and hematology. The biotechnology segment consists of R&D Systems' Biotechnology Division, Fortron (through June 30, 2007 when it was merged into R&D Systems' Biotechnology Division), BiosPacific and R&D China, which develop, manufacture and sell biotechnology research and diagnostic products world-wide. R&D Systems Europe distributes Biotechnology Division products throughout Europe. The hematology segment develops and manufactures hematology controls and calibrators for sale world-wide.

Following is financial information relating to the Company's operating segments (in thousands):

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>9/30/07</th>
<th>9/30/06</th>
</tr>
</thead>
<tbody>
<tr>
<td>External sales</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biotechnology</td>
<td>$ 38,881</td>
<td>$ 35,922</td>
</tr>
<tr>
<td>R&amp;D Systems Europe</td>
<td>15,449</td>
<td>12,927</td>
</tr>
<tr>
<td>Hematology</td>
<td>3,657</td>
<td>3,502</td>
</tr>
<tr>
<td>Total consolidated net sales</td>
<td>$ 57,987</td>
<td>$ 52,351</td>
</tr>
</tbody>
</table>

| Earnings before income taxes |         |         |
| Biotechnology | $ 27,367| $ 24,468|
| R&D Systems Europe | 7,752   | 5,350   |
| Hematology | 870     | 907     |
| Corporate and equity method investees | (1,236) | (1,013) |
| Total earnings before income taxes | $ 34,753 | $ 29,712 |
D. STOCK OPTIONS:

Option activity under the Company's stock option plans during the three months ended September 30, 2007 was as follows:

<table>
<thead>
<tr>
<th></th>
<th>WEIGHTED AVG. SHARES (in 000's)</th>
<th>WEIGHTED EXERCISE PRICE</th>
<th>CONTRACTUAL LIFE (Yrs.)</th>
<th>INTRINSIC AGGREGATE VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outstanding at June 30, 2007</td>
<td>423</td>
<td>$43.29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granted</td>
<td>3</td>
<td>56.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercised</td>
<td>(70)</td>
<td>34.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forfeited or expired</td>
<td>(1)</td>
<td>36.50</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outstanding at September 30, 2007</td>
<td>355</td>
<td>$45.23</td>
<td>5.50</td>
<td>$6.3 million</td>
</tr>
<tr>
<td>Exercisable at September 30, 2007</td>
<td>297</td>
<td>$43.08</td>
<td>5.25</td>
<td>$5.9 million</td>
</tr>
</tbody>
</table>

The fair value of options granted under the Company's stock option plans were estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions used:

- **Dividend yield**: --
- **Expected annualized volatility**: 24%-30% 31%-35%
- **Risk free interest rate**: 4.5%-4.6% 4.9%-5.1%
- **Expected life**: 4-5 years 4-5 years
- **Weighted average fair value of options granted**: $18.37 $18.29

The Company has not paid cash dividends and does not have any plans to do so, therefore an expected dividend yield of zero was used to estimate fair value of options granted. The expected annualized volatility is based on the Company's historical stock price over a period equivalent to the expected life of the option granted. The risk-free interest rate is based on U.S. Treasury constant maturity interest rate with a term consistent with the expected life of the options granted. Separate groups of employees that have similar historical exercise behavior with regard to option exercise timing and forfeiture rates are considered separately in determining option fair value.

The total intrinsic value of options exercised during the quarters ended September 30, 2007 and 2006 were $1.9 million and $55,000, respectively. Stock option exercises are satisfied through the issuance of new shares. The total fair value of options vested during the quarters ended September 30, 2007 and 2006 were $51,000 and $57,000, respectively.

Stock-based compensation cost of $170,000 and $165,000 was included in selling, general and administrative expense for the quarters ended September 30, 2007 and 2006, respectively. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. As of September 30, 2007, there was $694,000 of total unrecognized compensation cost related to nonvested stock options that will be expensed over fiscal years 2008 through 2010.

E. COMPREHENSIVE INCOME:

Comprehensive income and the components of other comprehensive income were as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>QUARTER ENDED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9/30/07</td>
</tr>
<tr>
<td>Dividend yield</td>
<td>--</td>
</tr>
<tr>
<td>Expected annualized volatility</td>
<td>24%-30% 31%-35%</td>
</tr>
<tr>
<td>Risk free interest rate</td>
<td>4.5%-4.6% 4.9%-5.1%</td>
</tr>
<tr>
<td>Expected life</td>
<td>4-5 years 4-5 years</td>
</tr>
<tr>
<td>Weighted average fair value of options granted</td>
<td>$18.37 $18.29</td>
</tr>
</tbody>
</table>

The total intrinsic value of options exercised during the quarters ended September 30, 2007 and 2006 were $1.9 million and $55,000, respectively. Stock option exercises are satisfied through the issuance of new shares. The total fair value of options vested during the quarters ended September 30, 2007 and 2006 were $51,000 and $57,000, respectively.

Stock-based compensation cost of $170,000 and $165,000 was included in selling, general and administrative expense for the quarters ended September 30, 2007 and 2006, respectively. Compensation cost is recognized using a straight-line method over the vesting period and is net of estimated forfeitures. As of September 30, 2007, there was $694,000 of total unrecognized compensation cost related to nonvested stock options that will be expensed over fiscal years 2008 through 2010.
Net earnings $ 23,072 $ 19,631
Other comprehensive gain, net of tax effect:
Foreign currency translation adjustments 2,217 806
Unrealized gain on available-for-sale investments 405 576
Comprehensive income $ 25,694 $ 21,013

F. INCOME TAXES:
The Company adopted FIN 48 on July 1, 2007. The adoption of FIN 48 did not result in a cumulative effect adjustment to retained earnings upon adoption. FIN 48 did not materially impact the consolidated financial statements for the quarter ended September 30, 2007. At September 30, 2007, unrecognized tax benefits were $126,000, including $53,000 of unrecognized tax benefits that, if recognized, would affect the effective tax rate. Accrued interest and penalties were not material at September 30, 2007.

The Company does not believe it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease in the next twelve months. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. The Company files income tax returns in the U.S federal tax jurisdiction, the states of Minnesota and California, and several jurisdictions outside the U.S. U.S. tax returns for 2004 and subsequent years remain open to examination by the tax authorities. The Company's major non-U.S. tax jurisdictions are the United Kingdom, France and Germany, which have tax years open to exam for 2004 and subsequent years.

ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Results of Operations for the Quarter Ended September 30, 2007 and the Quarter Ended September 30, 2006

Overview
TECHNE Corporation and Subsidiaries (the Company) are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted domestically through its wholly-owned subsidiary, Research and Diagnostic Systems, Inc (R&D Systems). The Company's wholly-owned U.K. subsidiary, R&D Systems Europe Ltd. (R&D Europe) distributes R&D Systems' biotechnology products throughout Europe. R&D Europe has a sales subsidiary, R&D Systems GmbH, in Germany and a sales office in France.


The Company has three reportable operating segments based on the nature of products and geographic location: biotechnology, R&D Systems Europe and hematology. The biotechnology segment consists of R&D Systems' Biotechnology Division, Fortron (through June 30, 2007), BiosPacific and R&D China, which develop, manufacture and sell biotechnology research and diagnostic products world-wide. R&D Systems Europe distributes Biotechnology Division products throughout Europe. The hematology segment develops and manufactures hematology controls and calibrators for sale world-wide.
Overall Results

Consolidated net earnings increased 17.5% for the quarter ended September 30, 2007 compared to the quarter ended September 30, 2006. The primary reason for the increase in consolidated net earnings was increased consolidated net sales. Consolidated net sales for the quarter ended September 30, 2007, increased 10.8% from the same period in the prior year. The favorable impact on consolidated net sales of the change from the prior year in exchange rates used to convert R&D Europe results from British pound sterling to U.S. dollars was $1.1 million for the quarter ended September 30, 2007. The favorable impact on consolidated net earnings of the change from the prior year in exchange rates was $403,000 for the quarter ended September 30, 2007.

The Company generated cash of $22.6 million from operating activities in the first quarter of fiscal 2008 and cash, cash equivalents and available-for-sale investments were $279 million at September 30, 2007 compared to $256 million at June 30, 2007.

Net Sales

Consolidated net sales for the quarter ended September 30, 2007 were $58.0 million, an increase of $5.6 million (10.8%) from the quarter ended September 30, 2006. Biotechnology net sales increased $3.0 million (8.2%) for the quarter ended September 30, 2007 primarily due to $2.9 million in increased U.S. sales volume by the Biotechnology Division. Sales for the quarter to pharmaceutical/biotechnology customers and academic customers, the two largest end-user groups of the Biotechnology Division U.S. market, showed the greatest revenue growth over the prior year.

R&D Europe net sales increased $2.5 million (19.5%) for the quarter ended September 30, 2007. The effect of changes from the prior year in foreign currency exchange rates used to convert British pounds to U.S. dollars increased R&D Europe net sales approximately $1.1 million for the quarter ended September 30, 2007. In British pounds, R&D Europe net sales increased 10.7% for the quarter ended September 30, 2007, mainly as a result of increased sales volume.

The Company has target annual sales growth rates for each of its business segments. The target sales growth rates, which are based on historical sales growth, are 10%-11% for biotechnology, 7%-8% for R&D Europe (in constant currency) and 1%-2% for hematology. Based on the relative size of each segment, the consolidated target annual growth rate is 8%-10% excluding the effect of changes in exchange rates.

Gross Margins

Gross margins, as a percentage of net sales, were as follows:

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>9/30/07</th>
<th>9/30/06</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology</td>
<td>80.2%</td>
<td>79.6%</td>
</tr>
<tr>
<td>R&amp;D Europe</td>
<td>54.6%</td>
<td>52.2%</td>
</tr>
<tr>
<td>Hematology</td>
<td>38.2%</td>
<td>40.1%</td>
</tr>
<tr>
<td>Consolidated gross margin</td>
<td>79.1%</td>
<td>78.5%</td>
</tr>
</tbody>
</table>

Consolidated gross margins, as a percentage of net sales, increased primarily due to an increase in R&D Europe gross margins and a change in sales mix from lower margin hematology sales to higher margin biotechnology sales as a result of different sales growth rates. R&D Europe's gross margin percentages for the quarter ended September 30, 2007 were greater than the comparable prior-year period as a result of favorable exchange rates.

The Company values its manufactured protein and antibody inventory based on a two-year forecast. Quantities in excess of the two-year forecast are considered impaired and not included in the inventory value. Sales of previously impaired protein and antibody inventory for the quarters ended September 30, 2007 and 2006 were not material.

Selling, General and Administrative Expenses
Selling, general and administrative expenses for the quarter ended September 30, 2007, increased $1.0 million (14.5%) from the same period of last year. Selling, general and administrative expenses are composed of the following (in thousands):

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>9/30/07</th>
<th>9/30/06</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology</td>
<td>$ 4,624</td>
<td>$ 4,013</td>
</tr>
<tr>
<td>R&amp;D Europe</td>
<td>2,262</td>
<td>2,020</td>
</tr>
<tr>
<td>Hematology</td>
<td>467</td>
<td>398</td>
</tr>
<tr>
<td>Corporate</td>
<td>737</td>
<td>636</td>
</tr>
<tr>
<td>Total selling, general and administrative expenses</td>
<td>$ 8,090</td>
<td>$ 7,067</td>
</tr>
</tbody>
</table>

Biotechnology selling, general and administrative expenses increased $611,000 (15.2%) for the quarter ended September 30, 2007. The increase for the quarter was due to a $205,000 increase in profit sharing expense from the same prior-year quarter and R&D China selling, general and administrative expenses of $99,000 for the quarter ended September 30, 2007. The remainder of the increase was mainly the result of annual wage and salary increases and the hiring of two additional marketing and administrative personnel.

The increase in R&D Europe selling, general and administrative expenses of $242,000 (12.0%) for the quarter ended September 30, 2007 was primarily due to the change in exchange rates from the prior year used to convert from British pound sterling to U.S. dollars. In British pound sterling, R&D Europe selling, general and administrative expenses increased 3.7% for the quarter ended September 30, 2007.

Research and Development Expenses

Research and development expenses are composed of the following (in thousands):

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>9/30/07</th>
<th>9/30/06</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biotechnology</td>
<td>$ 5,002</td>
<td>$ 4,675</td>
</tr>
<tr>
<td>Hematology</td>
<td>179</td>
<td>180</td>
</tr>
<tr>
<td>Total research and development expenses</td>
<td>$ 5,181</td>
<td>$ 4,855</td>
</tr>
</tbody>
</table>

Other Non-operating Expense and Income

Other non-operating expense and income consists mainly of foreign currency transaction gains and losses, rental income, building expenses related to rental property, and the Company's share of losses by equity method investees.

<table>
<thead>
<tr>
<th>QUARTER ENDED</th>
<th>9/30/07</th>
<th>9/30/06</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreign currency (gains) losses</td>
<td>$ (164)</td>
<td>$ 147</td>
</tr>
<tr>
<td>Rental income</td>
<td>(67)</td>
<td>(299)</td>
</tr>
<tr>
<td>Real estate taxes, depreciation and utilities</td>
<td>544</td>
<td>510</td>
</tr>
<tr>
<td>Hemerus Medical, LLC losses</td>
<td>131</td>
<td>127</td>
</tr>
<tr>
<td>Nephromics, LLC losses</td>
<td>125</td>
<td>--</td>
</tr>
<tr>
<td>Total other non-operating expense</td>
<td>$ 569</td>
<td>$ 485</td>
</tr>
</tbody>
</table>

The Company currently holds an 18% equity interest in Hemerus Medical, LLC (Hemerus) and at September 30, 2007, the Company’s net investment in Hemerus was $3.0 million. The Company accounts for its investment in Hemerus using the equity method of accounting because Hemerus is a limited liability company. The Company has financial exposure to the losses of Hemerus to the extent of its net investment in that entity. Hemerus’s success is dependent, in part, upon its ability to raise financing and to receiving Federal Drug
Administration (FDA) clearance to market its products. If such financing or FDA clearance is not received, the Company would potentially recognize an impairment loss to the extent of its remaining net investment.

In September 2006, the Company invested $7.2 million for an 18% equity interest in Nephromics, LLC (Nephromics). The Company accounts for its investment in Nephromics using the equity method of accounting because Nephromics is a limited liability company. At September 30, 2007, the Company's net investment in Nephromics was $6.6 million. The Company has financial exposure to any losses of Nephromics to the extent of its net investment in that entity.

Income Taxes

Income taxes for the quarters ended September 30, 2007 and 2006 were provided at rates of 33.6% and 33.9%, respectively, of consolidated earnings before income taxes. U.S. federal taxes have been reduced by the credit for research and development expenditures, the benefit for extraterritorial income through December 2006 and the manufacturer's deduction available under the American Jobs Creation Act of 2004. Foreign income taxes have been provided at rates that approximate the tax rates in the countries in which R&D Europe and R&D China operate. Without significant business developments, the Company expects income tax rates for the remainder of fiscal 2008 to range from approximately 33.5% to 34.5%.

Liquidity and Capital Resources

At September 30, 2007, cash and cash equivalents and available-for-sale investments were $279 million compared to $256 million at June 30, 2007. The Company believes it can meet its future cash, working capital and capital addition requirements through currently available funds, cash generated from operations and maturities of available-for-sale investments. The Company has an unsecured line of credit of $750,000. The interest rate on the line of credit is at prime. There were no borrowings on the line in the prior or current fiscal year.

Cash Flows From Operating Activities

The Company generated cash of $22.6 million from operating activities in the first quarter of fiscal 2008 compared to $19.4 million in the first quarter of fiscal 2007. The increase from the prior year was primarily due to an increase in net earnings in the current year of $3.4 million.

Cash Flows From Investing Activities

Capital expenditures for fixed assets for the first quarter of fiscal 2008 and 2007 were $3.2 million and $1.9 million, respectively. Included in capital expenditures for the first quarter of fiscal 2008 and 2007 were $2.7 million and $1.6 million, respectively, for building renovation and construction. The remaining capital additions in the first quarter of fiscal 2008 and 2007 were for laboratory and computer equipment. Expenditures for laboratory and computer equipment in the remainder of fiscal 2008 are expected to be approximately $2.5 million. The Company is currently constructing additional laboratory space and renovating laboratory space at its Minneapolis facility. Additional construction costs are estimated at $1.0 million and are expected to be completed in fiscal 2008. These expenditures are expected to be financed through currently available funds and cash generated from operating activities.

During the quarter ended September 30, 2007, the Company purchased $19.2 million and had sales or maturities of $6.1 million of available-for-sale investments. During the quarter ended September 30, 2006, the Company purchased $4.3 million and had sales or maturities of $2.6 million of available-for-sale investment. The Company's investment policy is to place excess cash in bonds and other investments with maturities of less than three years. The objective of this policy is to obtain the highest possible return with minimal risk, while keeping the funds accessible.

In September 2006, the Company invested $7.2 million for an 18% equity interest in Nephromics, LLC. The investment was financed through cash and equivalents on hand.
Cash Flows From Financing Activities

Cash of $2.3 million and $146,000 was received during the quarters ended September 30, 2007 and 2006, respectively, from the exercise of stock options. The Company also recognized excess tax benefits from stock option exercises of $328,000 and $24,000 for the quarters ended September 30, 2007 and 2006, respectively.

In the first quarter of fiscal 2008 and 2007, the Company purchased 23,641 shares and 22,400 shares of common stock, respectively, for its employee stock bonus plans at a cost of $1.5 million and $1.2 million, respectively.

The Company has never paid cash dividends and has no plans to do so in fiscal 2008.

Critical Accounting Policies

The Company's significant accounting policies are discussed in the Company's Annual Report on Form 10-K for fiscal 2007. The application of certain of these policies require judgments and estimates that can affect the results of operations and financial position of the Company. Judgements and estimates are used for, but not limited to, accounting for the allowance for doubtful accounts, inventory valuation and allowances, impairment of goodwill, intangibles and other long-lived assets, accounting for investments and income taxes. There have been no significant changes in estimates in fiscal 2008 which would require disclosure. There have been no changes to the Company's policies in fiscal 2008.

Recent Accounting Pronouncements

In June 2006, the FASB issued Interpretation No. 48 (FIN 48), Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109. Effective July 1, 2007, the Company adopted FIN 48. FIN 48 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements. The Statement establishes a single authoritative definition of fair value, sets out a framework for measuring fair value, and requires additional disclosures about fair value measurements. SFAS No. 157 applies only to fair value measurements that are already required or permitted by other accounting standards and is effective for the Company in fiscal 2009. The Company is currently evaluating the impact of adopting SFAS No. 157.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities. The Statement permits entities to choose to measure certain financial instruments at fair value. Unrealized gains and losses on items for which the fair value option has been elected are reported in earnings at each subsequent reporting date. SFAS No. 159 is effective for the Company in fiscal 2009. The Company is currently evaluating the impact of adopting SFAS No. 159.

Forward Looking Information and Cautionary Statements

This filing contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements include those regarding the Company's expectations as to target sales growth rates, compensation expense resulting from stock option expensing, the effective tax rate, the sufficiency of currently available funds for meeting the Company's needs and capital expenditures. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, the retention of hematology OEM (private label) and proficiency
survey business, the impact of currency exchange rate fluctuations, the costs
and results of research and product development efforts of the Company and of
companies in which the Company has invested or with which it has formed
strategic relationships, and the success of financing efforts by companies in
which the Company has invested. For additional information concerning such
factors, see the Company's Annual Report on Form 10-K as filed with the
Securities and Exchange Commission.

ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

At September 30, 2007, the Company had a professionally managed investment
portfolio of fixed income securities, excluding those classified as cash and
cash equivalents, of $103 million. These securities, like all fixed income
instruments, are subject to interest rate risk and will decline in value if
market interest rates increase.

The Company operates internationally, and thus is subject to potentially
adverse movements in foreign currency rate changes. The Company is exposed to
market risk from foreign exchange rate fluctuations of the euro, the British
pound sterling and the Chinese yuan to the U.S. dollar as the financial
position and operating results of the Company's U.K. subsidiary, European
operations and Chinese subsidiary are translated into U.S. dollars for
consolidation. At the current level of R&D Europe operating results, a 10%
increase or decrease in the average exchange rate used to translate operating
results into U.S. dollars would have an approximate $2.0 million effect on
consolidated operating income annually.

The Company's exposure to foreign exchange rate fluctuations also arises from
transferring funds from the U.K. and Chinese subsidiaries to the U.S.
subsidiary and from transferring funds from the German subsidiary and French
sales office to the U.K. subsidiary. At September 30, 2007 and 2006, the
Company had $3.2 million and $540,000, respectively, of dollar denominated
intercompany debt at its U.K. subsidiary and at September 30, 2007, the
Company had $119,000 dollar denominated intercompany debt at its Chinese
subsidiary. At September 30, 2007 and 2006, the U.K. subsidiary had $481,000
and $345,000, respectively, of dollar denominated intercompany debt from its
European operations. These intercompany balances are revolving in nature and
are not deemed to be long-term balances. The Company's U.K. subsidiary
recognized net foreign currency gains of 96,000 British pound sterling
($198,000) for the quarter ended September 30, 2007 and net foreign currency
losses of 78,000 British pound sterling ($147,000) for the quarter ended
September 30, 2006. The Company's Chinese subsidiary recognized net foreign
currency loss of 255,000 Chinese yuan ($34,000) for the quarter ended
September 30, 2007. The Company does not enter into foreign exchange forward
contracts to reduce its exposure to foreign currency rate changes on
intercompany foreign currency denominated balance sheet positions.

ITEM 4 - CONTROLS AND PROCEDURES

As of the end of the period covered by this report, the Company conducted an
evaluation, under the supervision and with the participation of the principal
executive officer and principal financial officer, of the Company's
disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-
15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")). Based
on this evaluation, the principal executive officer and principal financial
officer concluded that the Company's disclosure controls and procedures are
effective to ensure that information required to be disclosed by the Company
in reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in
Securities and Exchange Commission rules and forms. There was no change in
the Company's internal control over financial reporting during the Company's
most recently completed fiscal quarter that has materially affected, or is
reasonably likely to materially affect, the Company's internal control over
financial reporting.
ITEM 1 - LEGAL PROCEEDINGS

None.

ITEM 1A. - RISK FACTORS

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A, "Risk Factors," of the Company's Annual Report on Form 10-K for the year ended June 30, 2007.

ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table sets forth the repurchases of Company common stock for the quarter ended September 30, 2007:

<table>
<thead>
<tr>
<th>Period</th>
<th>Total Number of Shares Purchased</th>
<th>Maximum Approximate Dollar Value of Shares as Part of Plans or Programs</th>
<th>Total Number of Shares Purchased Publicly</th>
<th>Price Paid Per Share</th>
<th>Shares that May Yet Be Purchased Under Plans or Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>7/1/07-7/31/07</td>
<td>0</td>
<td>$6.8 million</td>
<td>0</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>8/1/07-8/31/07</td>
<td>0</td>
<td>$6.8 million</td>
<td>0</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>9/1/07-9/30/07</td>
<td>23,641</td>
<td>$63.17</td>
<td>0</td>
<td>$6.8 million</td>
<td></td>
</tr>
</tbody>
</table>

In May 1995, the Company announced a plan to purchase and retire its common stock. Repurchases of $40 million were authorized as follows: May 1995 - $5 million; April 1997 - $5 million; January 2001 - $10 million; October 2002 - $20 million. The plan does not have an expiration date.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 - SUBMISSION OF MATTERS TO VOTE OF SHAREHOLDERS

a. The Annual Meeting of the Registrant's shareholders was held on Thursday, October 25, 2007.

b. A proposal to set the number of directors at eight was adopted by a vote of 37,741,059 in favor with 31,683 shares against, and 12,980 shares abstaining.

c. Proxies for the Annual Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934. There was no solicitation in opposition to management's nominees as listed in the Proxy Statement, and all such nominees were elected as follows:

<table>
<thead>
<tr>
<th>Nominee</th>
<th>For</th>
<th>Withheld</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas E. Oland</td>
<td>37,553,591</td>
<td>232,135</td>
</tr>
<tr>
<td>Roger C. Lucas</td>
<td>37,360,051</td>
<td>425,675</td>
</tr>
<tr>
<td>Howard V. O'Connell</td>
<td>35,339,570</td>
<td>2,446,156</td>
</tr>
<tr>
<td>G. Arthur Herbert</td>
<td>37,243,798</td>
<td>541,928</td>
</tr>
<tr>
<td>Randolph C. Steer</td>
<td>37,229,939</td>
<td>555,787</td>
</tr>
<tr>
<td>Robert V. Baumgartner</td>
<td>37,251,609</td>
<td>534,117</td>
</tr>
<tr>
<td>Charles A. Dinarello</td>
<td>37,592,929</td>
<td>192,797</td>
</tr>
<tr>
<td>Karen A. Holbrook</td>
<td>37,589,407</td>
<td>196,319</td>
</tr>
</tbody>
</table>

ITEM 5 - OTHER INFORMATION
ITEM 6 - EXHIBITS

See exhibit index following.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TECHNE CORPORATION
(Company)

Date: November 8, 2007 /s/ Thomas E. Oland

President, Chief Executive Officer

/s/ Gregory J. Melsen

Chief Financial Officer

EXHIBIT INDEX
TO
FORM 10-Q

TECHNE CORPORATION

<table>
<thead>
<tr>
<th>Exhibit #</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>31.1</td>
<td>Section 302 Certification</td>
</tr>
<tr>
<td>31.2</td>
<td>Section 302 Certification</td>
</tr>
<tr>
<td>32.1</td>
<td>Section 906 Certification</td>
</tr>
<tr>
<td>32.2</td>
<td>Section 906 Certification</td>
</tr>
</tbody>
</table>
CERTIFICATION

I, Thomas E. Oland, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Techne Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:

   a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

   b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

   c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

   d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

   a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

   b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 8, 2007

/s/ Thomas E. Oland

Chief Executive Officer
CERTIFICATION

I, Gregory J. Melsen, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Techne Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
   
   a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
   b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
   c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
   d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

   a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
   
   b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 8, 2007

/s/ Gregory J. Melsen

Gregory J. Melsen
Chief Financial Officer
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Techne Corporation (the "Company")
On Form 10-Q for the quarter ended September 30, 2007 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
Thomas E. Oland, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or
15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.

/s/ Thomas E. Oland

-------------------------
Chief Executive Officer
November 8, 2007
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Techne Corporation (the "Company")
On Form 10-Q for the quarter ended September 30, 2007 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I,
Gregory J. Melsen, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or
15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations
of the Company.

/s/ Gregory J. Melsen
-------------------------
Chief Financial Officer
November 8, 2007